Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total versus corrected body weight dosing of sugammadex in morbidly obese patients
2014-005052-25Phase 3Active
- Sponsor
- Azienda Ospedaliero-Universitaria di Padova
- Start
- May 2015
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of Sugammadex in neuromuscular block (NMB) (2 arms), sponsored by Azienda Ospedaliero-Universitaria di Padova. Primary endpoint: Time to complete recovery of TOF ratio ≥1. Started May 2015; status: active.
02
Drugs
Sugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2014-005052-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005052-25.